MOSPD2: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

Target Name: MOSPD2

NCBI ID: G158747

MOSPD2

MOSPD2: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

MOSPD2 (Mesothelin-Specific Overlaying Protein-2) is a protein that is expressed in various tissues throughout the body, including the skin, bone, and connective tissues. It is a member of the mesothelin family, which is known for its role in cell-cell adhesion and barrier formation.

Recent studies have identified MOSPD2 as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because MOSPD2 has been shown to play a role in the development and progression of these conditions, and may be involved in the regulation of important cellular processes that are altered in these diseases.

One of the key mechanisms by which MOSPD2 is involved in the development of cancer is its role in cell-cell adhesion. MOSPD2 is a strong adhesion molecule that is expressed in many different types of cancer, including breast, ovarian, and prostate cancer. It has been shown to promote the growth and survival of cancer cells, and may contribute to their invasive and metastatic properties.

In addition to its role in cell-cell adhesion, MOSPD2 has also been shown to be involved in the regulation of important signaling pathways that are involved in cancer development. For example, studies have shown that MOSPD2 can interact with the protein PDGF-BB, which is a key regulator of cell-cell adhesion and growth. This interaction may be involved in the regulation of cell proliferation and survival, and may contribute to the development of cancer.

Another potential mechanism by which MOSPD2 may be involved in the development of neurodegenerative diseases is its role in the regulation of the extracellular matrix (ECM). ECM is a complex tissue matrix that is involved in the support and structure of many different types of cells, including neurons and glial cells. MOSPD2 has been shown to be involved in the regulation of ECM dynamics, and may play a role in the development and progression of neurodegenerative diseases.

MOSPD2 has also been shown to be involved in the regulation of important immune responses. It has been shown to interact with the protein PD-L1, which is a negative regulator of immune responses. This interaction may be involved in the regulation of immune cell function, and may contribute to the development of autoimmune disorders.

In conclusion, MOSPD2 is a protein that has been shown to be involved in a variety of cellular processes that are important for the development and progression of cancer, neurodegenerative diseases, and autoimmune disorders. As such, it is a potential drug target or biomarker for these conditions, and may be a useful agent for the development of new treatments for these diseases. Further research is needed to fully understand the role of MOSPD2 in these processes, and to determine its potential as a drug or biomarker.

Protein Name: Motile Sperm Domain Containing 2

Functions: Endoplasmic reticulum-anchored receptor which modulates interorganelle contacts by interacting with other organelle-bound proteins via their FFAT motif (PubMed:29858488). Might have a more important role in endoplasmic reticulum and endosomes contacts (PubMed:29858488). Promotes migration of primary monocytes and neutrophils, in response to various chemokines (PubMed:28137892)

The "MOSPD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MOSPD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets